Results 61 to 70 of about 5,775 (200)

PLEKHA5, PLEKHA6, and PLEKHA7 bind to PDZD11 to target the Menkes ATPase ATP7A to the cell periphery and regulate copper homeostasis. [PDF]

open access: yes, 2021
Copper homeostasis is crucial for cellular physiology and development, and its dysregulation leads to disease. The Menkes ATPase ATP7A plays a key role in copper efflux, by trafficking from the Golgi to the plasma membrane upon cell exposure to elevated ...
Xiao, Tong   +19 more
core   +1 more source

3T3-L1-ATP7A+/− adipocytes are enlarged and have increased triglyceride levels.

open access: yes, 2018
(A) Schematic of the Cas9/sgRNA targeting of ATP7A. The sgRNA-targeting sequence is shown; the PAM sequence is labeled in red. The results of sequencing of ATP7A genomic regions are shown below the WT sequence.
Michael J. Wolfgang (701096)   +9 more
core   +1 more source

DataSheet1_Heterogeneous nuclear ribonucleoprotein hnRNPA2/B1 regulates the abundance of the copper-transporter ATP7A in an isoform-dependent manner.PDF

open access: yes, 2022
Copper (Cu) is an essential micronutrient with a critical role in mammalian growth and development. Imbalance of Cu causes severe diseases in humans; therefore, cellular Cu levels are tightly regulated.
Nesrin M. Hasan (14213111)   +4 more
core   +1 more source

The P-type ATPase transporter ATP7A promotes angiogenesis by limiting autophagic degradation of VEGFR2

open access: yesNature Communications, 2021
The role of endothelial copper transporter ATP7A in vascular function and angiogenesis remains largely unexplored. Here the authors show that ATP7A promotes VEGFR2 signaling and angiogenesis by limiting autophagy-mediated degradation of VEGFR2, which ...
Dipankar Ash   +10 more
doaj   +1 more source

EP300‐Mediated MTF1‐K218 Lactylation Buffers AR‐Driven Copper Overload to Suppress Cuproptosis in Castration‐Resistant Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li   +21 more
wiley   +1 more source

Characterization of Atp7afl/+; Clnd6Cre+/− heterozygous female mice.

open access: yes, 2013
A) Patches of hypopigmentation are observed in the coats of weanling heterozygous Atp7afl/+; Clnd6Cre+/− females. B) Kaplan-Meier plot showing postnatal survival of heterozygous Atp7afl/+; Clnd6Cre+/− female (n = 16) and littermate control Atp7a ...
Gary A. Weisman (36992)   +4 more
core   +1 more source

A State‐Gated Metallo‐DNAzyme Framework Programs Tumor Stress Vulnerability Through Metabolic Licensing

open access: yesAdvanced Science, EarlyView.
A tumor‐state‐gated metallo‐DNAzyme framework integrates miR‐21/APE1‐responsive GLUT1 silencing with Ca/Cu‐partitioned metal–nucleic acid assembly and cystine loading. The framework first weakens glucose‐dependent metabolic buffering and then amplifies copper‐ and disulfide‐associated stress, converting tumor metabolic adaptation into programmable ...
Xiaodong Ma   +8 more
wiley   +1 more source

Frequency of offspring with global deletion of the Atp7a gene.

open access: yes, 2013
The numbers of live-born offspring or embryos at day 10.5 post coitus (E10.5) are shown for each genotype resulting from a cross between Atp7afl/+ females and Atp7a+/Y; Cldn6Cre+/+ males.
Gary A. Weisman (36992)   +4 more
core   +1 more source

Two highly polymorphic CA repeats in the Menkes gene (ATP7A) [PDF]

open access: yesHuman Genetics, 1995
Two highly polymorphic CA repeats have been identified in the Menkes gene (ATP7A). These repeats should be useful for prenatal diagnosis and carrier detection in families with Menkes disease and X-linked cutis laxa. The observed heterozygosity for these two repeats was 0.778 and 0.60 in Centre d'Etude du Polymorphisme Humaine (CEPH) families.
Glover, Thomas W.   +3 more
openaire   +3 more sources

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

open access: yesBMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy